Biosimilars

The interests of payors, physicians, and patients must be addressed for biosimilars to offer cost savings.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases.

Biosimilar infliximab-dyyb (Inflectra) treats a variety of autoimmune diseases, including Crohn’s disease, rheumatoid arthritis, and psoriatic arthritis.

Policy decisions will affect how much biosimilars improve patient access to advanced treatments.

Most read articles of the week on Specialty Pharmacy Times.

The Generic Pharmaceutical Association and its Biosimilars Council are pleased that the Food and Drug Administration (FDA) has issued its draft guidance on biosimilar labeling.

Access to biologics increased by as much as 100% after biosimilars became available.

Biosimilars face scrutiny before they can be indicated for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis.

Although only 1 biosimilar has been approved in the United States thus far, pharmacists can expect to see a lot more action in this space in the next few years.

Controversy swirls around the naming protocol for biosimilars among drug manufacturers and the FDA.

There are several ongoing global phase 3 clinical trials for biosimilar adalimumab, which treats conditions such as rheumatoid arthritis, psoriatic arthritis, and Crohn's Disease.

A summary of the clinical potential of biosimilar therapies and special considerations for older patients with cancer.

The drug is the first biosimilar monoclonal antibody to be considered by the FDA.

Pharmacists must understand the potential value of biosimilars as a competitive generation of more cost efficient drugs hit the market.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the potential of biosimilars to reduce the cost burden of specialty pharmaceuticals.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

An understanding of biosimilars will be essential for patient consults and education.

Treatment helps reduce infection risk from low white blood cell count in cancer patients receiving chemotherapy.

Several states have enacted more stringent laws that still require prescriber notification or authorization prior to dispensing an interchangeable biosimilar.

Office of Generic Drugs will no longer require final printed labeling to approve Abbreviated New Drug Applications.

Tumor necrosis factor alpha inhibitor can also treat autoimmune diseases such as rheumatoid arthritis and psoriasis.

David Lassen, chief clinical officer at Prime Therapeutics, discusses the potential long term impact from biosimilars on the specialty drug landscape.

Doug Long, vice president of industry relations at IMS Health, discusses if health care providers will be hesitant to prescribe biosimilars.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group, discusses the projected ramifications from the launch of biosimilars in the United States.